To assess the efficacy and adverse effects of Oxcarbazepine and Brivaracetam in children with self limited focal epilepsies by intervention for a duration of 6 months.

Assessment of the efficacy of Oxcarbazepine and Brivaracetam in children with self limited focal epilepsies (SeLFEs) An open label Randomized controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/065485

Enrollment

Registered

2024-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset

Interventions

Intervention1: Brivaracetam: weight dependant dose, PO,twice a day, for a duration of 6 months Control Intervention1: Oxcarbazepine: weight dependant dose, PO, twice a day for a duration of 6 months

Eligibility

Inclusion criteria

Inclusion criteria: children between 2 years and 18 years of age with SeLFEs caregiver giving consent for participation caregiver willing for follow up

Exclusion criteria

Exclusion criteria: Children with Epilepsies other than SeLFEs caregiver not giving consent children with known allergies to Oxcarbazepine or Brivaracetam past history of renal impairment, SJS, psychosis or suicidal ideation.

Design outcomes

Primary

Measure	Time frame
1.The efficacy of Oxcarbazepine and Brivaracetam in the reduction of seizure frequency in children with SeLFEsTimepoint: 6 months	—

Secondary

Measure	Time frame
1.Adverse effects of Oxcarbazepine and Brivaracetam during the study period 2.cognitive performance of children with SeLFEs after treatment with Oxcarbazepine and Brivaracetam. Timepoint: 6 months	—

Countries

India

Contacts

Public ContactDr Lokesh Saini

AIIMS Jodhpur

drlokeshsaini@gmail.com9968859725

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026